PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.36%
Some net income increase while CRVO is negative at -75.00%. John Neff would see a short-term edge over the struggling competitor.
-22.93%
Negative yoy D&A while CRVO is 372.78%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
18.38%
Deferred tax of 18.38% while CRVO is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-40.28%
Both cut yoy SBC, with CRVO at -7.16%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
112.09%
Slight usage while CRVO is negative at -785.19%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
86.72%
A yoy AP increase while CRVO is negative at -94.90%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
300.21%
Some yoy usage while CRVO is negative at -1981.22%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-40.28%
Negative yoy while CRVO is 63.76%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
17.79%
Some CFO growth while CRVO is negative at -41.59%. John Neff would note a short-term liquidity lead over the competitor.
19.38%
Some CapEx rise while CRVO is negative at -550.01%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
99.99%
Growth well above CRVO's 100.00%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
98.29%
Investing outflow well above CRVO's 96.28%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
684.38%
Issuance growth of 684.38% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.